Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-089 · 5 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | Highest ABT-089 dose |
| 5 | ACTIVE_COMPARATOR | atomoxetine |
| 6 | PLACEBO_COMPARATOR | placebo |
| Name | Type | Description |
|---|---|---|
| ABT-089 | DRUG | Subjects will take up to 80 mg daily for 24 months |
| Placebo | DRUG | Subjects will take one or two placebos once daily for the duration of the study. |
| atomoxetine | DRUG | Subjects will take 10, and/or 18 and/or 25 mg atomoxetine tablets once daily for 8 weeks. |
Inclusion Criteria: * The subject was randomized into Study M10-346 and completed the study. * Female subjects of childbearing potential must have a negative urine pregnancy test at screening and baseline and agree to comply with applicable contraceptive requirements. * Male subjects must agree to ...
ABT-089 is an investigational small molecule developed by AbbVie Inc. for Attention Deficit Hyperactivity Disorder. It has been studied in Phase 2 clinical trials in both adults and children with ADHD. It is not an approved treatment and remains in clinical development.
ABT-089 was studied as a potential treatment for Attention Deficit Hyperactivity Disorder in adults and children. Its Phase 2 program evaluated safety, tolerability, and efficacy in these populations. No approved use has been established for ABT-089.
ABT-089 is developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie sponsored the Phase 2 clinical program evaluating the compound in Attention Deficit Hyperactivity Disorder.
ABT-089 is in Phase 2 development. Five Phase 2 trials have been completed, and no trials are currently active. The studies enrolled a total of 817 participants with Attention Deficit Hyperactivity Disorder.
ABT-089 has been evaluated in five completed Phase 2 trials, including NCT00686933, NCT00640419, NCT00640185, and NCT00528697. These studies assessed safety, tolerability, and efficacy in adults and children with Attention Deficit Hyperactivity Disorder, with enrollment ranging from 117 to 278 participants.
The ABT-089 Phase 2 trials were randomized, double-blind, and placebo-controlled. They enrolled 817 participants total across adult and pediatric Attention Deficit Hyperactivity Disorder populations, with studies conducted in the United States. All five trials have been completed.